Description
The Duration and Safety of Osteoporosis Treatment, 1st ed. 2016
Anabolic and Antiresorptive Therapy
Coordinators: Silverman Stuart, Abrahamsen Bo
Language: EnglishSubjects for The Duration and Safety of Osteoporosis Treatment:
Support: Print on demand
Description
/li>Contents
/li>Biography
/li>Comment
/li>
Providing a comprehensive review of short-and long-term adverse events of both antiresorptive and anabolic drugs, this practical guide updates the clinician on the pathophysiology of osteoporosis and the principles behind our present and future pharmaceuticals. Leading practitioners in the field examine all current literature and data regarding the duration and safety of these therapies, with recommendations for clinicians on decision-making and best practices for osteoporosis patients. An overview of the pathophysiology and epidemiology of osteoporosis and discussion of both anabolic and antiresorptive drugs is followed by fracture risk assessment and an examination of treatment failures. Next, a number of chapters are dedicated to the diagnosis, presentation and management of atypical femur fractures and osteonecrosis of the jaw (ONJ), each of which are significant patient concerns when using these osteoporosis treatments. The introduction and utilization of drug holidays is also discussed, as well as the long-term outlook for management of osteoporotic patients. Written and edited by experts in the field, The Duration and Safety of Osteoporosis Treatment is a balanced resource for researchers, practitioners and policy-makers alike for clinical decision-making and patient care.
Foreword Juliet Compston
Preface
Chapter 1 Osteoporosis: Pathophysiology & Epidemiology
Rebecca J. Moon, Cyrus Cooper, and Nicholas C. Harvey
Chapter 2 Antiresorptives
R. Graham G. Russell, Maria K. Tsoumpra, Frank H. Ebetino, Michael Pazianas
Chapter 3 Anabolics
Erik Fink Eriksen
Chapter 4 Tools for Assessing Fracture Risk and for Treatment Monitoring
William D. Leslie, Lisa M. Lix, and Suzanne N. Morin
Chapter 5 Treatment Failure
Elisa Torres del Pliego, Daniel Prieto-Alhambra, and Adolfo Díez-Perez
Chapter 6 Epidemiology of Atypical Subtrochanteric and Femoral Shaft Fractures
Jeri W. Nieves
Chapter 7 Bisphosphonate-Related Atypical Femoral Fractures and Their Radiographic Features
Joseph C. Giaconi and C. Travis Watterson
Chapter 8 Factors Contributing to Atypical Femoral Fractures
Adele L. Boskey and Marjolein C. H. van der Meulen
Chapter 9 Clinical Presentation of Atypical Femur Fractures
Yelena Bogdan and Thomas A. Einhorn
Chapter 10 Effects of Antiresorptive Therapy on Bone Microarchitecture
Joy N. T
sai and Mary L. BouxseinChapter 11 Management of Atypical Femoral Fractures
Joseph M. Lane, Libi Z. Galmer, David S. Wellman, Abigail L. Campbell, Jonathan E. Jo
Chapter 12 Osteonecrosis of the Jaw: Clinico-Pathologic and Radiologic Features
Parish P. Sedghizadeh and Allan C. Jones
Chapter 13 Epidemiology of Osteonecrosis of the Jaws from Antiresorptive Treatment
Morten Schiødt
Chapter 14 Management of Osteonecrosis of the Jaw in Patients Receiving Antiresorptive Treatment
Morten Schiødt
Chapter 15 Long-Term Efficacy and Safety of Treatments for Osteoporosis
Socrates E. Papapoulos
Chapter 16 Management of Drug Holidays
Christian Roux and Karine Briot
Chapter 17 Patients Who Do Not Take Their Osteoporosis Medications: Can We Help Them Become Compliant?
Deborah T. Gold
Chapter 18 Fractures and Healing on Antiresorptive Therapy
Eli Kupperman and Susan V. Bukata
Chapter 19 Antiresorptive Therapy and Mortality and Cancer Incidence
Peter Vestergaard
Chapter 20 Other Safety Concerns
Michael R. McClung
Chapter 21 The Impact of Regulatory and Scientific Organizations Recommendations on Clinical Decision Making
Alexandra Papaioannou, Arnav Agarwal, and Sarah Karampatos
Chapter 22 Integrated Clinical View on Long-Term Management of Patients with Osteoporosis
E. Michael Lewiecki
Chapter 23 Conclusions
Stuart L. Silverman and Bo Abrahamsen
Stuart L. Silverman, MD, FACP, FACR
Cedars-Sinai Medical Center
Division of Rheumatology
Department of Medicine
Los Angeles, CA, USA
University of California Los Angeles
David Geffen School of Medicine
Los Angeles, CA, USA
Bo Abrahamsen, MD, PhD
University of Southern Denmark
Odense Patient Data Explorative Network
Institute of Clinical Research
Odense, Denmark
Holbæk Hospital
Department of Medicine
Holbæk, Denmark
Focuses on the duration and safety of anabolic and antiresorptive drug therapies for osteoporosis
Examines common and serious side effects of extended drug treatment, especially bisphosphonates
Discusses diagnosis and management of osteonecrosis of the jaw and atypical femur fractures